Astellas/Medivation seek EU expanded Xtandi mCRPC use
This article was originally published in Scrip
Executive Summary
Astellas Pharma and partner Medivation have submitted a market authorization application in Europe for the expanded use of Xtandi (enzalutamide) in chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) patients.